Laboratory monitoring of low-molecular-weight heparin therapy

Is laboratory monitoring of low-molecular-weight heparin

The issue of how and when to monitor low-molecular-weight heparin (LMWH) therapy was raised from the beginning of the clinical use of these compounds, almost 20 years ago. Laboratory monitoring of LMWHwas suggested mainly because the new compounds were to replace unfractionated heparin (UFH), which definitely required monitoring. In the following, we will briefly review the reasons for monitori...

Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes.

Low Molecular Weight Heparin Overdose: A 10 Year Case Series

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

Determination of low molecular weight heparin in clinical laboratory.

The applicability was investigated of automated spectrophotometric heparin assays and three clotting assays for determination of two low molecular weight (LMW) heparin fractions: Org 10172 and DxN10 and two infractionated commercially available heparins. The relative activity of the two commercially available heparins was similar in the anti-Xa assay, in the anti-IIa assay and in 3 clotting ass...

Low molecular weight heparin.